こちらは会員限定サービスです。 会員登録でWeb講演会やeディテールといったMReachのコンテンツのご利用が 可能になるほか、ポイントプログラム ...

Highlighted text has been updated as of December 23, 2024. The DanGer Shock trial showed that routine implantation of Impella CP on top of standard care is superior to standard care alone in reducing ...

As veno-arterial extracorporeal membrane oxygenation was unavailable, mechanical chest compression was performed and an Impella device was used that immediately delivered at 3.2 l/min flow to reach ...

Implantation of the Impella CP micro-axial flow pump may increase survival at six months among patients with STEMI complicated by cardiogenic shock (CS), according to the results of the DanGer Shock ...

This Is a Humanitarian Use Protocol for the Impella RP® System which is indicated for providing circulatory assistance for up to 14 days in pediatric or adult patients with a body surface area ≥ 1.5 ...

Introduction The use of Impella in the setting of high-risk percutaneous coronary intervention (PCI) has been introduced in clinical practice in the last few years in selected hospitals, giving a ...

The Impella 5.5 with SmartAssist [Image courtesy of Johnson & Johnson MedTech] Johnson & Johnson MedTech today announced the FDA has expanded its approval of Impella heart pumps to treat specific ...

The year held a number of surprises, including a few negative studies, as well as a big win for Impella in DanGer Shock.

The patient was placed on percutaneous mechanical circulatory support with Impella CP and transferred for emergent mitral valve replacement. This case highlights the potential complications of ...

The US Food and Drug Administration (FDA) has granted premarket approval (PMA) to Johnson & Johnson (J&J) MedTech’s Impella 5.5 with SmartAssist and Impella CP with SmartAssist heart pumps ...

One medical device found to be in the top five medical devices related to industry payments was Impella, a device used in ...